Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Brentuximab Vedotin after Allo-SCT for Hodgkin Lymphoma
NCT03540849Phase 2Unknown
- Sponsor
- CHU Caen Normandie
- Start
- Mar 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by CHU Caen Normandie. Primary endpoint: Cumulative Incidence of Relapse or Progression at 12 months. Status: unknown.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03540849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540849.